X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3300) 3300
Publication (186) 186
Conference Proceeding (20) 20
Book Review (14) 14
Book Chapter (7) 7
Magazine Article (5) 5
Newsletter (3) 3
Book / eBook (1) 1
Data Set (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2347) 2347
deferoxamine - therapeutic use (1961) 1961
male (1422) 1422
deferoxamine (1209) 1209
female (1141) 1141
animals (999) 999
index medicus (891) 891
adult (851) 851
iron chelating agents - therapeutic use (725) 725
iron (614) 614
adolescent (601) 601
deferoxamine - pharmacology (579) 579
child (577) 577
iron - metabolism (565) 565
hematology (499) 499
desferrioxamine (490) 490
rats (461) 461
deferoxamine - administration & dosage (408) 408
middle aged (402) 402
deferiprone (346) 346
ferritins - blood (333) 333
child, preschool (328) 328
iron overload - drug therapy (325) 325
chelation therapy (312) 312
blood transfusion (297) 297
iron overload (295) 295
mice (295) 295
thalassemia (294) 294
pyridones - therapeutic use (291) 291
beta-thalassemia (288) 288
pharmacology & pharmacy (288) 288
transfusion reaction (277) 277
beta-thalassemia - drug therapy (270) 270
oxidative stress (268) 268
deferoxamine - adverse effects (265) 265
biochemistry & molecular biology (252) 252
deferasirox (227) 227
iron chelating agents - pharmacology (224) 224
thalassemia - drug therapy (223) 223
iron - blood (221) 221
thalassemia - therapy (211) 211
iron overload - etiology (207) 207
overload (206) 206
therapy (197) 197
aged (196) 196
beta-thalassemia - complications (195) 195
oncology (192) 192
drug therapy, combination (189) 189
chelating agents - therapeutic use (188) 188
iron chelating agents - administration & dosage (186) 186
siderophores - therapeutic use (183) 183
time factors (175) 175
benzoates - therapeutic use (174) 174
triazoles - therapeutic use (173) 173
disease models, animal (165) 165
treatment outcome (165) 165
beta-thalassemia - therapy (163) 163
chelation (161) 161
iron chelating agents - adverse effects (160) 160
thalassemia major (157) 157
liver - metabolism (155) 155
pediatrics (155) 155
ferritin (153) 153
infant (145) 145
survival (144) 144
toxicology (142) 142
iron - urine (140) 140
iron chelation (139) 139
toxicity (139) 139
administration, oral (135) 135
free radicals (133) 133
iron - poisoning (133) 133
medicine, general & internal (133) 133
rats, sprague-dawley (131) 131
renal dialysis - adverse effects (131) 131
dose-response relationship, drug (129) 129
thalassemia - complications (129) 129
analysis (128) 128
neurosciences (125) 125
young adult (125) 125
health aspects (122) 122
disease (119) 119
apoptosis (117) 117
hemosiderosis - drug therapy (116) 116
rats, wistar (115) 115
care and treatment (112) 112
cells, cultured (112) 112
chelation-therapy (112) 112
lipid-peroxidation (110) 110
endocrinology & metabolism (109) 109
complications (106) 106
magnetic resonance imaging (106) 106
antioxidants (103) 103
hemochromatosis - drug therapy (103) 103
metabolism (103) 103
chelating agents (102) 102
medicine (99) 99
article (98) 98
liver (98) 98
pyridones - administration & dosage (97) 97
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3000) 3000
German (72) 72
Italian (71) 71
French (66) 66
Spanish (24) 24
Japanese (23) 23
Russian (17) 17
Polish (13) 13
Czech (5) 5
Chinese (4) 4
Portuguese (4) 4
Dutch (3) 3
Romanian (3) 3
Hebrew (2) 2
Serbian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Danish (1) 1
Korean (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Haematology, ISSN 0902-4441, 06/2012, Volume 88, Issue 6, pp. 535 - 548
Objectives:  Iron‐overload cardiomyopathy is a major cause of morbidity and mortality in patients with thalassemia. However, the precise mechanisms of iron... 
calcium channel | iron overload | cardiac iron | left ventricular function | heart rate variability | Iron overload | Cardiac iron | Calcium channel | Heart rate variability | Left ventricular function | MALONDIALDEHYDE | QUANTIFICATION | CA2+ CHANNELS | CARDIAC MYOCYTES | RATS | CARDIOMYOCYTES | TRANSFERRIN-BOUND IRON | HEART-RATE-VARIABILITY | IRON-OVERLOAD CARDIOMYOPATHY | HEMATOLOGY | EXPRESSION | beta-Thalassemia - pathology | Humans | Calcium Channel Blockers - therapeutic use | beta-Thalassemia - genetics | Deferoxamine - therapeutic use | Azoles - therapeutic use | DNA Primers - genetics | Iron, Dietary - administration & dosage | RNA, Messenger - metabolism | Cardiovascular System - physiopathology | Verapamil - therapeutic use | Base Sequence | Nifedipine - therapeutic use | Nitrophenols - therapeutic use | Calcium Channels, T-Type - genetics | Organoselenium Compounds - therapeutic use | Disease Models, Animal | Iron - blood | Heart Rate | Iron Chelating Agents - therapeutic use | Mice, Inbred C57BL | RNA, Messenger - genetics | Ventricular Function, Left - drug effects | Organophosphorus Compounds - therapeutic use | beta-Thalassemia - physiopathology | Cardiovascular System - drug effects | Iron - metabolism | Mice, Knockout | Dihydropyridines - therapeutic use | beta-Thalassemia - drug therapy | Organ Size - drug effects | Animals | Calcium Channels, L-Type - genetics | Calcium Channels, L-Type - drug effects | Calcium Channels, T-Type - drug effects | Mice
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2018, Volume 281, pp. 139 - 177
Journal Article
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2008, Volume 105, Issue 43, pp. 16761 - 16766
Journal Article
Drugs, ISSN 0012-6667, 7/2010, Volume 70, Issue 11, pp. 1381 - 1394
The management of the myelodysplastic syndromes (MDS) requires insight into the complex biology of the disease. Despite this challenge, two recent developments... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Myelodysplastic- syndromes, treatment | Lenalidomide, therapeutic use | Research-and-development | Erythropoietins, therapeutic use | Decitabine, therapeutic use | Romiplostim, therapeutic use | Histone-deacetylase- inhibitors, therapeutic use | Azacitidine, therapeutic use | Darbepoetin-alfa, therapeutic use | Farnesyl-transferase-inhibitors, therapeutic use | Antithymocyte-globulin, therapeutic use | Deferasirox, therapeutic use | Granulocyte-colony-stimulating-factors, therapeutic use | Clofarabine, therapeutic use | Deferoxamine, therapeutic use | LOW-RISK | COLONY-STIMULATING FACTOR | RESPONSE CRITERIA | PHASE-II | ANTITHYMOCYTE GLOBULIN | PHARMACOLOGY & PHARMACY | VALPROIC ACID | TOXICOLOGY | ACUTE MYELOID-LEUKEMIA | INTERMEDIATE-RISK | INTERNATIONAL WORKING GROUP | DARBEPOETIN-ALPHA | Drugs, Investigational - pharmacology | Recombinant Fusion Proteins - pharmacology | Adenine Nucleotides - pharmacology | Humans | Immunosuppressive Agents - therapeutic use | Recombinant Fusion Proteins - therapeutic use | Drugs, Investigational - therapeutic use | Thrombopoietin - therapeutic use | Thalidomide - pharmacology | Receptors, Fc - therapeutic use | Thalidomide - analogs & derivatives | Anemia - drug therapy | Farnesyltranstransferase - antagonists & inhibitors | Immunosuppressive Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Bone Marrow - physiopathology | Iron Chelating Agents - therapeutic use | Risk Factors | Arabinonucleosides - pharmacology | Adenine Nucleotides - therapeutic use | Farnesyltranstransferase - therapeutic use | Piperazines - therapeutic use | Thrombopoietin - pharmacology | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Arabinonucleosides - therapeutic use | Farnesyltranstransferase - pharmacology | Iron Chelating Agents - pharmacology | Pyrimidines - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Histone Deacetylase Inhibitors - therapeutic use | Benzamides | Thalidomide - therapeutic use | DNA Methylation - drug effects | Antimitotic agents | Care and treatment | Prognosis | Dosage and administration | Research | Antineoplastic agents | Myelodysplastic syndromes
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 01/2011, Volume 96, Issue 1, pp. 41 - 47
Journal Article